美国变态反应、哮喘和免疫学院(AAAAI)和美国变态反应、哮喘和免疫医师协会(ACAAI)联合发表声明：孟鲁司特与自杀的
2008/04/07
Joint statement on FDA investigation of Singulair
from the AAAAI and ACAAI
MILWAUKEE - Leadership from the American Academy of Allergy Asthma & Immunology and the American College of Allergy, Asthma & Immunology today released the following statement in response to the Thursday announcement of a Food and Drug Administration investigation into Singulair:
There are no data from well-designed studies to indicate a link between Singulair and suicide. The concern expressed by the FDA is based entirely on case reports and there is no indication that such effects apply to other leukotriene-modifying medications.
Post-marketing case reports are incomplete. Furthermore, comparative data are lacking on the incidence of suicide in the general population versus the incidence in patients taking Singulair. Thus, it is unknown whether there is an increased incidence of suicide in patients receiving Singulair.
Based on the information currently available, patients taking Singulair should continue to take the medication as prescribed provided: 1) the patient and physician feel the medication is effective; and 2) the patient does not experience any suicidal behavior or thoughts.
Patients who experience suicidal thoughts or demonstrate suicidal behavior should consult their physician immediately to discuss whether to continue with this medication. Patients should not hesitate to consult their physician if they feel uncomfortable continuing on the medication.
（华子）
上一篇：
关于开展2008“世界哮喘日”宣传活动的通知
下一篇：
“咳嗽诊治指南”修订工作启动
